Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$26.79 +0.0%	$28.40	$23.23 ▼ $42.29	$860.82M	0.76	444,130 shs	214,645 shs
ETNB 89bio	$6.94 +0.6%	$7.63	$4.16 ▼ $11.84	$1.01B	1.25	1.32 million shs	906,074 shs
TERN Terns Pharmaceuticals	$2.92 -4.3%	$3.02	$1.87 ▼ $11.40	$254.91M	-0.13	1.53 million shs	806,225 shs
WVE Wave Life Sciences	$6.73 -0.9%	$8.49	$4.25 ▼ $16.74	$1.03B	-0.93	1.22 million shs	1.04 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	0.00%	-0.81%	-9.37%	-17.80%	-24.49%
ETNB 89bio	0.00%	+14.52%	-22.54%	-2.66%	-19.11%
TERN Terns Pharmaceuticals	0.00%	+21.41%	-6.41%	-35.11%	-38.53%
WVE Wave Life Sciences	0.00%	+13.68%	-25.31%	-43.96%	+34.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	3.9188 of 5 stars	3.4	1.0	3.0	2.2	0.8	2.5
ETNB 89bio	3.0057 of 5 stars	4.4	1.0	0.0	3.4	1.7	0.6
TERN Terns Pharmaceuticals	4.2944 of 5 stars	3.3	2.0	4.1	4.0	3.3	0.6
WVE Wave Life Sciences	4.2965 of 5 stars	3.5	1.0	4.8	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.60	62.75% Upside
ETNB 89bio	2.89	Moderate Buy	$27.25	292.65% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$18.38	529.28% Upside
WVE Wave Life Sciences	3.00	Buy	$22.18	229.60% Upside

Current Analyst Ratings Breakdown

Latest TERN, WVE, ETNB, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/21/2025	TERN Terns Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/8/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/8/2025	WVE Wave Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00
3/26/2025	WVE Wave Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/22/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
3/21/2025	TERN Terns Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/14/2025	ETNB 89bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$11.00
3/13/2025	ETNB 89bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.36	$9.71 per share	2.76	$5.99 per share	4.47
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$4.13 per share	N/A
WVE Wave Life Sciences	$108.30M	9.54	N/A	N/A	$0.40 per share	16.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$48.15M	$1.86	11.55	4.45	N/A	14.78%	104.67%	18.38%	5/8/2025 (Estimated)
ETNB 89bio	-$142.19M	-$3.43	N/A	N/A	N/A	N/A	-59.58%	-52.21%	5/8/2025 (Estimated)
TERN Terns Pharmaceuticals	-$90.21M	-$1.13	N/A	N/A	N/A	N/A	-32.76%	-31.33%	5/12/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.79	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	5/8/2025 (Estimated)

Latest TERN, WVE, ETNB, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TERN Terns Pharmaceuticals	-$0.29	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	N/A	N/A	N/A	$174.96 million	N/A
5/8/2025	Q1 2025	ETNB 89bio	-$0.50	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	WVE Wave Life Sciences	-$0.26	N/A	N/A	N/A	$11.65 million	N/A
3/20/2025	Q4 2024	TERN Terns Pharmaceuticals	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A
3/6/2025	Q4 2024	ETNB 89bio	-$0.60	-$1.02	-$0.42	-$1.02	N/A	N/A
3/4/2025	Q4 2024	WVE Wave Life Sciences	-$0.17	$0.17	+$0.34	$0.17	$25.60 million	$83.75 million
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.43	0.97	0.88
ETNB 89bio	0.09	11.66	11.66
TERN Terns Pharmaceuticals	N/A	32.99	32.99
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
ETNB 89bio	N/A
TERN Terns Pharmaceuticals	98.26%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
ETNB 89bio	2.80%
TERN Terns Pharmaceuticals	15.10%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
ETNB 89bio	40	145.98 million	103.15 million	Optionable
TERN Terns Pharmaceuticals	40	87.30 million	72.11 million	Not Optionable
WVE Wave Life Sciences	240	153.49 million	108.14 million	Optionable

TERN, WVE, ETNB, and COLL Headlines

Recent News About These Companies

Russell Investments Group Ltd. Purchases 43,398 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

April 26 at 3:29 AM | marketbeat.com

Adage Capital Partners GP L.L.C. Has $119.03 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 25 at 7:46 AM | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.18 Consensus Target Price from Analysts

April 25 at 1:53 AM | americanbankingnews.com

Wave Life Sciences (NASDAQ:WVE) Shares Up 10.7% - Still a Buy?

April 23, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Buy" by Brokerages

April 23, 2025 | marketbeat.com

M28 Capital Management LP Sells 500,000 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

April 22, 2025 | marketbeat.com

Jump Financial LLC Makes New Investment in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 22, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Short Interest Update

April 22, 2025 | marketbeat.com

Short Interest in Wave Life Sciences Ltd. (NASDAQ:WVE) Increases By 19.2%

April 21, 2025 | americanbankingnews.com

Franklin Resources Inc. Trims Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 20, 2025 | marketbeat.com

EAM Investors LLC Purchases Shares of 214,717 Wave Life Sciences Ltd. (NASDAQ:WVE)

April 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Raised by Geode Capital Management LLC

April 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Stake Lowered by Walleye Capital LLC

April 18, 2025 | marketbeat.com

Federated Hermes Inc. Invests $841,000 in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 18, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Trading 5.4% Higher - Still a Buy?

April 17, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Affinity Asset Advisors LLC

April 17, 2025 | marketbeat.com

Martingale Asset Management L P Decreases Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 17, 2025 | marketbeat.com

Research Analysts Issue Forecasts for WVE FY2026 Earnings

April 15, 2025 | marketbeat.com

Norges Bank Invests $1.24 Million in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 14, 2025 | marketbeat.com

Vanguard Group Inc. Raises Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

April 14, 2025 | marketbeat.com

What is Wedbush's Forecast for WVE Q1 Earnings?

April 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?
By Jea Yu | April 23, 2025
View S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?
Top 3 S&P 500 Winners in a Losing Market
By Ryan Hasson | April 9, 2025
View Top 3 S&P 500 Winners in a Losing Market
2 Penny Stocks With $10 Potential
By Thomas Hughes | April 16, 2025
View 2 Penny Stocks With $10 Potential
Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AI
By Jeffrey Neal Johnson | April 7, 2025
View Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AI
2 Strong Utilities Plays With Booming Earnings and Room to Grow
By Nathan Reiff | April 24, 2025
View 2 Strong Utilities Plays With Booming Earnings and Room to Grow

TERN, WVE, ETNB, and COLL Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$26.79 +0.01 (+0.04%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$26.80 +0.02 (+0.06%)

As of 04/25/2025 04:20 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

89bio NASDAQ:ETNB

$6.94 +0.04 (+0.58%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$6.94 +0.00 (+0.07%)

As of 04/25/2025 06:31 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Terns Pharmaceuticals NASDAQ:TERN

$2.92 -0.13 (-4.26%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$2.92 0.00 (-0.14%)

As of 04/25/2025 04:49 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Wave Life Sciences NASDAQ:WVE

$6.73 -0.06 (-0.88%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$6.73 0.00 (0.00%)

As of 04/25/2025 06:42 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time